Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 2, 1998, Pages 133-139

  Steffens, M G ^a   Kranenborg, M H G C ^a   Boerman, O C ^a   Zegwaart Hagemeier, N E M ^a   Debruyne, F M J ^a   Corstens, F H M ^a   Oosterwijk, E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Internalization; Monoclonal antibody G250; Radiometals; Renal cell carcinoma; Tumor retention

Indexed keywords

IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDIUM; OLIGOPEPTIDE; ORGANOMETALLIC COMPOUND; PENTETIC ACID; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RHENIUM; RHENIUM MERCAPTOACETYLTRIGLYCINE; RHENIUM-MERCAPTOACETYLTRIGLYCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; GAMMA RADIATION; IMMUNE RESPONSE; INTERNALIZATION; ISOTOPE LABELING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; XENOGRAFT; ANIMAL; CELL CULTURE; HUMAN; KIDNEY TUMOR; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MICE; MICE, NUDE; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031593288     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.133     Document Type: Article

References (25)

1. 131I-B1 (anti-CD20) antibody therapy with autologues stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336.
2. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, and Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol, 1996;14:1974.
3. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD, Herskovic T, Hanley D and Goldenberg DM. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 23:1995;5899.
4. Wilder RB, Denardo GL and Denardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 14:1383.
5. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D and Bernstein ID. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123.
6. Duncan JR and Welch MJ. Intracellular metabolism of indium-111 -DTPA-labeled receptor targeted proteins. J Nucl Med 1993;34:1728.
7. Geissler F, Anderson SK, Venkatesan P and Press O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1993;52:2907.
8. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ. The processing and fete of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994;35:899.
9. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, GriffithsGL, Bair HJ, WolfFG, Becker WS and Goldenberg DM. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by canonic amino acids and their derivatives. Cancer Res 1995;55:3825.
10. Stein R, Goldenberg DM, Thorpe SR and Mattes MJ. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung. J Nucl Med 38:391.
11. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL and Goldenberg DM. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 1997;72:477.
12. Holtzman E. Lysosomes. Plenium Press, New York, 1989:95-100.
13. Reist CJ, Garg PK, Alston KL, Bigner DD and Zalutsky MR. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 1996;56:4970.
14. Visser GW, Gerretsen M, Herscheid JD, Snow GB and Van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 34:1953.
15. Kranenborg MHGC, Boerman OC, de Weijert MCA, Oosterwijk-Wakka JC, Corstens FHM and Oosterwijk E. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcionma xenografts. Cancer 1997;80:2390.
16. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J and Warnaar SO. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489.
17. Oosterwijk E, de Weijert M, van Bokhoven A, Brakenhoff RH, Peelen WP and Debruyne FMJ. Molecular characterization of the renal cell carcinoma associated antigen G250. Urol Res 1995;23:253.
18. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R and Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478.
19. Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531.
20. Fraker PJ and Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3,6-diphenylglucoril. Biochem Biophys Res Commun 1978;80:849.
21. Hnatowich DJ, Childs RL, Lanteigne D and Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods 1983;65:147.
22. Lindmo T, Boven E, Cuttitta F, Fedorko J and Bunn PA Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984,72:77.
23. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA and Goldenberg DM. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anticarcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997,38:858.
24. Griffiths GL, Goldenberg DM, Knapp FF, Callahan AP, Chang CH and Hansen HJ. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res 1991;51-4594.
25. Duncan JR, Stephenson MT, Wu HP and Anderson CJ. Indium-111-diethylenetriaminepentaacetic acidoctreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659.